408 related articles for article (PubMed ID: 9346488)
1. Transgenic knockout mice with exclusively human sickle hemoglobin and sickle cell disease.
Pászty C; Brion CM; Manci E; Witkowska HE; Stevens ME; Mohandas N; Rubin EM
Science; 1997 Oct; 278(5339):876-8. PubMed ID: 9346488
[TBL] [Abstract][Full Text] [Related]
2. Transgenic knockout mice exclusively expressing human hemoglobin S after transfer of a 240-kb betas-globin yeast artificial chromosome: A mouse model of sickle cell anemia.
Chang JC; Lu R; Lin C; Xu SM; Kan YW; Porcu S; Carlson E; Kitamura M; Yang S; Flebbe-Rehwaldt L; Gaensler KM
Proc Natl Acad Sci U S A; 1998 Dec; 95(25):14886-90. PubMed ID: 9843985
[TBL] [Abstract][Full Text] [Related]
3. Knockout-transgenic mouse model of sickle cell disease.
Ryan TM; Ciavatta DJ; Townes TM
Science; 1997 Oct; 278(5339):873-6. PubMed ID: 9346487
[TBL] [Abstract][Full Text] [Related]
4. A recombinant human hemoglobin with anti-sickling properties greater than fetal hemoglobin.
Levasseur DN; Ryan TM; Reilly MP; McCune SL; Asakura T; Townes TM
J Biol Chem; 2004 Jun; 279(26):27518-24. PubMed ID: 15084588
[TBL] [Abstract][Full Text] [Related]
5. Human sickle hemoglobin in transgenic mice.
Ryan TM; Townes TM; Reilly MP; Asakura T; Palmiter RD; Brinster RL; Behringer RR
Science; 1990 Feb; 247(4942):566-8. PubMed ID: 2154033
[TBL] [Abstract][Full Text] [Related]
6. A human embryonic hemoglobin inhibits Hb S polymerization in vitro and restores a normal phenotype to mouse models of sickle cell disease.
He Z; Russell JE
Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10635-40. PubMed ID: 12124399
[TBL] [Abstract][Full Text] [Related]
7. A second generation transgenic mouse model expressing both hemoglobin S (HbS) and HbS-Antilles results in increased phenotypic severity.
Fabry ME; Sengupta A; Suzuka SM; Costantini F; Rubin EM; Hofrichter J; Christoph G; Manci E; Culberson D; Factor SM; Nagel RL
Blood; 1995 Sep; 86(6):2419-28. PubMed ID: 7662990
[TBL] [Abstract][Full Text] [Related]
8. Magnetic resonance evidence of hypoxia in a homozygous alpha-knockout of a transgenic mouse model for sickle cell disease.
Fabry ME; Kennan RP; Paszty C; Costantini F; Rubin EM; Gore JC; Nagel RL
J Clin Invest; 1996 Dec; 98(11):2450-5. PubMed ID: 8958206
[TBL] [Abstract][Full Text] [Related]
9. Mouse models of sickle cell disease.
Beuzard Y
Transfus Clin Biol; 2008; 15(1-2):7-11. PubMed ID: 18502677
[TBL] [Abstract][Full Text] [Related]
10. Second generation knockout sickle mice: the effect of HbF.
Fabry ME; Suzuka SM; Weinberg RS; Lawrence C; Factor SM; Gilman JG; Costantini F; Nagel RL
Blood; 2001 Jan; 97(2):410-8. PubMed ID: 11154217
[TBL] [Abstract][Full Text] [Related]
11. Pathophysiology of a sickle cell trait mouse model: human alpha(beta)(S) transgenes with one mouse beta-globin allele.
Noguchi CT; Gladwin M; Diwan B; Merciris P; Smith R; Yu X; Buzard G; Fitzhugh A; Keefer LK; Schechter AN; Mohandas N
Blood Cells Mol Dis; 2001; 27(6):971-7. PubMed ID: 11831863
[TBL] [Abstract][Full Text] [Related]
12. Effect of fetal hemoglobin on microvascular regulation in sickle transgenic-knockout mice.
Kaul DK; Liu XD; Chang HY; Nagel RL; Fabry ME
J Clin Invest; 2004 Oct; 114(8):1136-45. PubMed ID: 15489961
[TBL] [Abstract][Full Text] [Related]
13. A transgenic mouse model of sickle cell disorder.
Greaves DR; Fraser P; Vidal MA; Hedges MJ; Ropers D; Luzzatto L; Grosveld F
Nature; 1990 Jan; 343(6254):183-5. PubMed ID: 2296310
[TBL] [Abstract][Full Text] [Related]
14. Transgenic mouse models of sickle cell disease.
Beuzard Y
Curr Opin Hematol; 1996 Mar; 3(2):150-5. PubMed ID: 9372066
[TBL] [Abstract][Full Text] [Related]
15. Short survival of phosphatidylserine-exposing red blood cells in murine sickle cell anemia.
de Jong K; Emerson RK; Butler J; Bastacky J; Mohandas N; Kuypers FA
Blood; 2001 Sep; 98(5):1577-84. PubMed ID: 11520810
[TBL] [Abstract][Full Text] [Related]
16. Anti-beta s-ribozyme reduces beta s mRNA levels in transgenic mice: potential application to the gene therapy of sickle cell anemia.
Alami R; Gilman JG; Feng YQ; Marmorato A; Rochlin I; Suzuka SM; Fabry ME; Nagel RL; Bouhassira EE
Blood Cells Mol Dis; 1999 Apr; 25(2):110-9. PubMed ID: 10389593
[TBL] [Abstract][Full Text] [Related]
17. Correction of the sickle cell mutation in embryonic stem cells.
Chang JC; Ye L; Kan YW
Proc Natl Acad Sci U S A; 2006 Jan; 103(4):1036-40. PubMed ID: 16407095
[TBL] [Abstract][Full Text] [Related]
18. In vivo demonstration of red cell-endothelial interaction, sickling and altered microvascular response to oxygen in the sickle transgenic mouse.
Kaul DK; Fabry ME; Costantini F; Rubin EM; Nagel RL
J Clin Invest; 1995 Dec; 96(6):2845-53. PubMed ID: 8675655
[TBL] [Abstract][Full Text] [Related]
19. Correction of sickle cell disease in transgenic mouse models by gene therapy.
Pawliuk R; Westerman KA; Fabry ME; Payen E; Tighe R; Bouhassira EE; Acharya SA; Ellis J; London IM; Eaves CJ; Humphries RK; Beuzard Y; Nagel RL; Leboulch P
Science; 2001 Dec; 294(5550):2368-71. PubMed ID: 11743206
[TBL] [Abstract][Full Text] [Related]
20. Correction of a mouse model of sickle cell disease: lentiviral/antisickling beta-globin gene transduction of unmobilized, purified hematopoietic stem cells.
Levasseur DN; Ryan TM; Pawlik KM; Townes TM
Blood; 2003 Dec; 102(13):4312-9. PubMed ID: 12933581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
